Transgender people and communities, including nonbinary people, have specific needs within harm reduction programs.
Breadcrumb
- Home
- Resources and Tools
Resources and Tools
A recent study published in Drug and Alcohol Dependence found evidence for racial/ethnic disparities in buprenorphine distribution across the United States.
In May, the New England AIDS Education Training Center (NEAETC) published a set of pages dedicated to providing information about and resources for HIV and HIV-related topics.
This document provides a quick overview of the federal discretionary funding programs that support essential aspects of the nation’s HIV response.
In recent years, the gap in the rate of opioid overdoses among Black and white Americans has narrowed significantly, with increases in Black mortality driven in part by the addition of synthetic opioids to other drugs.
Achieving the goals of the Ending the HIV Epidemic (EHE) Initiative depends on doing more to strengthen communities, reduce the harm associated with drug use, and prevent disease transmission.
This technical package, a collaborative effort between CDC and NASTAD, provides a broad framework as well as evidence-informed strategies and approaches to support the planning, design, implementation, and sustainability of new and existing syringe services programs (SSPs).
Opioid agonist treatment (OAT) is the provision of medications (methadone and buprenorphine) that activate the opioid receptors to prevent withdrawal and reduce cravings for opioids.
This publication, part of SAMHSA's Evidence Based Resource Guide series, addresses the co-occurrence of HIV and mental illness and/or SUD.
Pagination
- Previous page ‹‹
- Page 2
- Next page ››